26 studies found for:    MEK Inhibitor AZD-6244
Show Display Options
Rank Status Study
1 Completed Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Condition: Thyroid Cancer
Intervention: Biological: AZD6244
2 Completed MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
3 Completed Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Recruiting MEK Inhibitor and Thoracic Radiotherapy Trial
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AZD6244
5 Terminated Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
6 Terminated
Has Results
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: temsirolimus;   Drug: selumetinib;   Other: laboratory biomarker analysis
7 Active, not recruiting Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib
8 Recruiting A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Conditions: Cancer;   Non Small Cell Lung Cancer
Intervention: Drug: Vandetanib, Selumetinib
9 Not yet recruiting A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
Conditions: Biliary Tract Carcinoma;   Gallbladder Carcinoma
Interventions: Drug: Selumetinib;   Drug: Cisplatin;   Drug: Gemcitabine
10 Active, not recruiting Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
Conditions: Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate;   Drug: selumetinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Active, not recruiting MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Condition: Colorectal Neoplasms
Interventions: Drug: MK-2206;   Drug: AZD6244
12 Recruiting A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
13 Active, not recruiting AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
Conditions: Unresectable Hepatocellular Carcinoma;   Liver Cancer
Intervention: Drug: AZD6244 and sorafenib
14 Terminated Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Condition: Rectal Cancer
Interventions: Drug: AZD6244;   Drug: Cediranib (AZD2171)
15 Completed A Study of ARRY-142886 in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: ARRY-142886, MEK inhibitor; oral
16 Active, not recruiting Selumetinib in Cancers With BRAF Mutations
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
17 Active, not recruiting ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
Conditions: Biliary Tract Neoplasms;   Cholangiocarcinoma;   Gallbladder Neoplasms
Interventions: Drug: selumetinib;   Drug: gemcitabine;   Drug: cisplatin
18 Recruiting Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Drug: Selumetinib 75 mg;   Drug: Docetaxel 75 mg/m2;   Drug: Docetaxel 60 mg/m2;   Drug: Placebo
19 Recruiting AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
Conditions: Neurofibromatosis 1;   Neurofibromatosis Type 1;   NF 1;   Neurofibroma, Plexiform
Intervention: Drug: AZD6244 hyd sulfate
20 Recruiting Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Drug: Selumetinib;   Drug: Docetaxel;   Drug: Placebo;   Drug: Pegylated G-CSF

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
Indicates status has not been verified in more than two years